GLP-1 drugs linked to 41% lower obesity-related cancer risk
A large study of over 229,000 people found semaglutide and tirzepatide were associated with dramatically reduced risk of endometrial, pancreatic, colorectal, and multiple myeloma cancers.
- 41% overall reduction in obesity-related cancer risk among GLP-1 users.
- Endometrial, pancreatic, colorectal, and multiple myeloma showed >50% lower risk.
- Effect appears larger than weight loss alone can explain — GLP-1 receptors live on some tumors.
A new study published in Annals of Oncology analyzed health data from more than 229,000 obese, non-diabetic individuals and found a striking link between GLP-1 medications and reduced cancer risk.
41% overall reduction in obesity-related cancers
Participants who took GLP-1 medications containing semaglutide or tirzepatide saw a 41% decrease in their overall risk of developing an obesity-related cancer. Researchers noted this is a signal large enough to drive clinical guidelines if confirmed in prospective trials.
Four cancers saw 50% or greater risk reduction
- Endometrial cancer — 58% lower risk
- Pancreatic cancer — >50% lower risk
- Colorectal cancer — >50% lower risk
- Multiple myeloma — >50% lower risk
Why GLP-1s may protect beyond weight loss
Researchers believe the effect is more than just shedding pounds. GLP-1 receptors are expressed directly on certain cancer cells, suggesting the drug may act on tumors themselves. Weight loss still matters — excess fat promotes chronic inflammation and insulin resistance — but the biology appears to run deeper.
"The scale of this signal across a quarter-million patients is hard to ignore."
Source: Medical News Today
Ready to start your protocol?
A licensed physician reviews your profile and tailors treatment to you — typically within 24 hours.
Explore treatments
